Document is current
Any future updates will be listed below
-
Authors
Given, Katherine S
Acker, Elizabeth G
Macklin, Wendy B
Carlin, Dan
Owens, Gregory P.
Bennett, Jeffrey L
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals (RN2239)
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 28 April 2025
First Online: 12 June 2025
Declarations
:
: All procedures involving animals were performed in accordance with University of Colorado Institutional Animal Care and Use Committee policy for animal use in agreement with the NIH Guide for the Care and Use of Laboratory Animals.
: Not Applicable.
: KSG- None EA- None WBM- None DC - is an employee and shareholder of Alexion, AstraZeneca Rare Disease GPO- None JLB – reports personal fees from Alexion AstraZeneca Rare Disease, Antigenomycs, BeiGene, Chugai, Clene Nanomedicine, Genentech, Genzyme, Reistone Bio, Roche, Imcyse, Mitsubishi-Tanabe, and TG; speaker fees from Alexion; grants from Alexion and the National Institutes of Health. In addition, Dr Bennett has a patent ‘Compositions and methods for the treatment of neuromyelitis optica’.
